CONFERENCE SERIES: BioPharma Strategy
Recorded at: Accelerating Proof-of-Concept
Digital Course: Evidence Led Decision Making for Clinical Proof-of-Concepts
October 4, 2010
About this Product:
This tutorial offers an introduction to the fundamentals of Proof-of-Concept (PoC) in pharmaceutical drug development. The program covers everything from the root causes of attrition to the execution of a successful PoC program in a clinical trial. Learn how and why proof-of-concept studies fail and how to manage the risks associated.
Agenda At A Glance:
- Introduction to attrition and the productivity & economic impacts
- Interactive session to investigate attrition causes
- Group discussion on defining PoC and how far PoC decisions need to be made
- Discuss how and why things go wrong when a PoC fails
- Managing the types of risk being taken on at PoC
- Planning and executing PoC
- Q&A
Speaker Biographies:
John Arrowsmith
A PhD chemist by training, whose current role is as Science Director, Life Sciences Consulting , Thomson Reuters in London. Previously John was an Executive Director with Pfizer leading the Competitive Intelligence Group in R&D. John has a total of 30 year Biopharmaceutical Research and Development experience in drug discovery and development, intellectual property, licensing, portfolio information systems, portfolio prioritization, continuous improvement processes, performance measures and scorecards. John has worked in UK, US and Japan with his last 8 years being based at Pfizer’s R&D facility in Connecticut. John is the author/contributor to 2 books, 16 publications and 18 patents. Co-inventor of Tikosyn® an anti-arrhythmic drug.
Richard K. Harrison
Dr. Richard K. Harrison has over 30 years of experience in the life sciences industry. His career has focused on all aspects of pre-clinical drug discovery. During this time he has held positions of increasing responsibility at Aventis, Merck, DuPont and Wyeth Pharmaceuticals where he delivered numerous clinical candidates and worked on several marketed drugs. In addition, he served as a founding scientist in two successful venture funded computational and structure based drug design companies. Dr. Harrison has authored over 40 peer reviewed publications and book chapters in all areas of drug discovery and has presented over 50 invited lectures on these subjects, He earned his Ph.D. in Biophysical Chemistry and Enzymology and currently serves as an adjunct professor at several universities.
About this Product:
2 Presentations
Over 49 slides
58 minutes
Single Copy - $345.00
Site License - $1,380.00